Jakarta, April 12, 2025 - PT Etana Biotechnologies Indonesia (Etana) introduced two new products in collaboration with global partner BeiGene (tislelizumab) and BRUKINSA® (zanubrutinib) during the Etana Oncology Summit, which also served as a scientific forum to discuss the latest advancements in cancer therapies.
Read MoreJakarta, March 14, 2025 – In commemoration of World Kidney Day, Etana Biotechnologies Indonesia (Etana) reaffirms its commitment to supporting innovation in kidney disease treatment in Indonesia. As a biotechnology company, Etana actively contributes to providing high-quality and affordable medicines for patients, especially those suffering from kidney disease.
Read MoreJakarta, 5 February 2025 – In commemoration of World Cancer Day, Etana Biotechnologies Indonesia (Etana) reaffirmed its commitment to providing high-quality and affordable cancer treatment solutions. As a local biopharmaceutical company, Etana continues to innovate in developing and producing medicines that are accessible to cancer patients across Indonesia.
Read MoreJakarta, 25 January 2025 – PT Etana Biotechnologies Indonesia (Etana) reaffirms its commitment to supporting government programs aimed at strengthening domestic vaccine production as part of efforts to achieve national health resilience and independence.
Read MoreJakarta, December 10, 2024 – PT Etana Biotechnologies Indonesia (Etana), an Indonesian biopharmaceutical company, has obtained marketing authorization for two innovative cancer therapies, Tislelizumab (ETAPIDI®) and Zanubrutinib (BRUKINSA®). Developed by BeiGene, which plans to change its name to BeOne Medicines, a global oncology leader committed to making cutting-edge and accessible treatments available worldwide, these therapies are set to transform cancer care in Indonesia by combining global advancements with local accessibility.
Read MoreJakarta, 14 November 2024 – PT Etana Biotechnologies Indonesia (Etana), a local Indonesian biopharmaceutical company and Celltrion, a leading global biopharmaceutical company specialized in researching, developing and manufacturing innovative therapeutics medicine, today announced that the companies have entered a strategic distribution and marketing agreement for Herzuma® (trastuzumab) and Truxima® (rituximab). These two treatments are first-line targeted therapies for breast cancer and non-Hodgkin's lymphoma, and listed in the National Formulary (Fornas) and e-catalogue.
Read More
